Cargando…
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954727/ https://www.ncbi.nlm.nih.gov/pubmed/33625578 http://dx.doi.org/10.1007/s00432-021-03549-y |
| _version_ | 1783664135349731328 |
|---|---|
| author | Wiegel, Thomas Albers, Peter Bartkowiak, Detlef Bussar-Maatz, Roswitha Härter, Martin Kristiansen, Glen Martus, Peter Wellek, Stefan Schmidberger, Heinz Grozinger, Klaus Renner, Peter Schneider, Fried Burmester, Martin Stöckle, Michael |
| author_facet | Wiegel, Thomas Albers, Peter Bartkowiak, Detlef Bussar-Maatz, Roswitha Härter, Martin Kristiansen, Glen Martus, Peter Wellek, Stefan Schmidberger, Heinz Grozinger, Klaus Renner, Peter Schneider, Fried Burmester, Martin Stöckle, Michael |
| author_sort | Wiegel, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7954727 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79547272021-03-28 Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) Wiegel, Thomas Albers, Peter Bartkowiak, Detlef Bussar-Maatz, Roswitha Härter, Martin Kristiansen, Glen Martus, Peter Wellek, Stefan Schmidberger, Heinz Grozinger, Klaus Renner, Peter Schneider, Fried Burmester, Martin Stöckle, Michael J Cancer Res Clin Oncol Letter to the Editor Springer Berlin Heidelberg 2021-02-24 2021 /pmc/articles/PMC7954727/ /pubmed/33625578 http://dx.doi.org/10.1007/s00432-021-03549-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter to the Editor Wiegel, Thomas Albers, Peter Bartkowiak, Detlef Bussar-Maatz, Roswitha Härter, Martin Kristiansen, Glen Martus, Peter Wellek, Stefan Schmidberger, Heinz Grozinger, Klaus Renner, Peter Schneider, Fried Burmester, Martin Stöckle, Michael Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title | Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title_full | Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title_fullStr | Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title_full_unstemmed | Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title_short | Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) |
| title_sort | reply to andreas boehle, frank kahmann, thomas oliver henkel, joerg zimmermann and stefan machten’s to the letter to the editor re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (prefere trial) |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954727/ https://www.ncbi.nlm.nih.gov/pubmed/33625578 http://dx.doi.org/10.1007/s00432-021-03549-y |
| work_keys_str_mv | AT wiegelthomas replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT alberspeter replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT bartkowiakdetlef replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT bussarmaatzroswitha replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT hartermartin replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT kristiansenglen replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT martuspeter replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT wellekstefan replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT schmidbergerheinz replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT grozingerklaus replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT rennerpeter replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT schneiderfried replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT burmestermartin replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial AT stocklemichael replytoandreasboehlefrankkahmannthomasoliverhenkeljoergzimmermannandstefanmachtenstothelettertotheeditorreresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial |